---
title: Labcorp (LH) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/lh
ticker: LH
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Diagnostics & Research
---
# Labcorp (LH)

Labcorp (LH) closed at $317.95 on Oct 16, 2026, overvalued by 13% vs its model value of $280.40 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $317.95 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $280.40 |
| Price vs model | overvalued by 13% vs model |
| Range of that model | $150.79 – $848.96 |
| Market value | $25.8B |
| P/E (fiscal 2025) | 30.4 |
| Net margin (fiscal 2025) | 6.3% |
| Free cash flow (fiscal 2025) | $1.2B |
| Dividend yield (trailing twelve months) | 0.91% |
| Beta | 0.85 |
| Cost of capital (WACC) | 7.76% |
| Business classification | Mature & Stable (Low/slowing growth (~7% recent), Moderate margins (6% net margin), Highly cyclical earnings) |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 0.91% |
| Dividends per share, last 12 months | $2.88 |
| Dividends / free cash flow (fiscal 2025) | 20.0% |
| Raised | — |
| Growth over 3 years | 3.8% a year |
| Latest payment | $0.72, ex-date Aug 28, 2026, paid Sep 11, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Aug 7, 2023 | $2.58 |
| To Aug 29, 2024 | $2.88 |
| To Aug 28, 2025 | $2.88 |
| Trailing twelve months (to Aug 28, 2026) | $2.88 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $280.40 | $150.79 | $848.96 |
| DCF · Perpetuity growth · 10y | cross check | $304.45 | $171.89 | $877.35 |
| DCF · EBITDA exit · 5y | cross check | $348.41 | $226.38 | $492.25 |
| DCF · EBITDA exit · 10y | cross check | $360.48 | $229.78 | $535.18 |
| P/E · peers | cross check | $332.60 | $316.19 | $366.24 |
| P/E · own history | cross check | $366.82 | $204.49 | $446.66 |
| PEG | sanity check | $376.36 | $376.36 | $376.36 |
| EV/EBITDA · peers | cross check | $272.36 | $211.41 | $274.53 |
| EV/Revenue · peers | cross check | $825.54 | $393.34 | $1,284.02 |
| Earnings power value | cross check | $119.07 | $86.89 | $166.67 |
| Dividend discount | cross check | $75.46 | $51.19 | $126.78 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 5 open-market sales ($3.2M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 1, 2026 | Oyegunwa Akinbolade | EVP, CIO & CTO | Grant / award | 750 | $0 |
| Sep 1, 2026 | Meltzer Jonathan C | EVP, COO | Grant / award | 900 | $0 |
| Sep 1, 2026 | Vaughn Bryan T | EVP and President, Diagnostics | Grant / award | 1,500 | $0 |
| Sep 1, 2026 | Caveney Brian J | EVP, Pres of BLS, CMO & CSO | Grant / award | 3,000 | $0 |
| Aug 17, 2026 | ANDERSON KERRII B | Director | Open-market sell (10b5-1 plan) | 3,000 | $954,060 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Sep 30, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/920148/000092014826000207/lh-20260930.htm |
| Sep 22, 2026 | 8-K | 7.01 Regulation FD Disclosure | https://www.sec.gov/Archives/edgar/data/920148/000092014826000205/lh-20260922.htm |
| Sep 10, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/920148/000092014826000201/lh-20260910.htm |
| Aug 28, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/920148/000092014826000189/lh-20260828.htm |
| Aug 17, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/920148/000092014826000185/lh-20260817.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| John Rogers | 2026-06-30 | 349,112 | $97.8M |
| Wallace Weitz | 2026-06-30 | 99,050 | $27.7M |
| Jensen | 2026-06-30 | 16,050 | $4.5M |
| Bridgewater | 2026-06-30 | 2,798 | $783,440 |

4 tracked managers in all.

## About

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

---

Source: https://sweetvaluelab.com/stocks/lh (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.